Talis Biomedical Corp financial data

Symbol
TLIS on OTC
Industry
Laboratory Analytical Instruments
Location
1375 West Fulton Market, Suite 700, Chicago, IL
State of incorporation
DE
Fiscal year end
December 31
Former names
SlipChip Corp (to 10/17/2017)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 866 % -23.2%
Quick Ratio 13 %
Debt-to-equity 39.5 % +43%
Return On Equity -79.7 % -12.8%
Return On Assets -57.2 % -3.16%
Operating Margin -13.5K % -327%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.7M shares +732%
Common Stock, Shares, Outstanding 1.82M shares +0.17%
Entity Public Float 8.15B USD +11%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 1.82M shares +0.28%
Weighted Average Number of Shares Outstanding, Diluted 1.82M shares +0.28%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 408K USD -85.7%
Research and Development Expense 20.5M USD -64.1%
Costs and Expenses 55.5M USD -40.4%
Operating Income (Loss) -55.1M USD +38.9%
Net Income (Loss) Attributable to Parent -51M USD +40.5%
Earnings Per Share, Basic -28 USD/shares +56.6%
Earnings Per Share, Diluted -28 USD/shares +56.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.9M USD -39%
Inventory, Net 2.03M USD
Assets, Current 63.6M USD -37.6%
Property, Plant and Equipment, Net 425K USD -88%
Operating Lease, Right-of-Use Asset 7.91M USD -50.7%
Other Assets, Noncurrent 766K USD -50.3%
Assets 72.7M USD -40.9%
Accounts Payable, Current 3.79M USD +52.1%
Accrued Liabilities, Current 634K USD -32.4%
Liabilities, Current 8.2M USD -11.5%
Operating Lease, Liability, Noncurrent 15.9M USD -10%
Liabilities 24.1M USD -10.5%
Retained Earnings (Accumulated Deficit) -562M USD -9.99%
Stockholders' Equity Attributable to Parent 48.6M USD -49.4%
Liabilities and Equity 72.7M USD -40.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.43M USD +61%
Net Cash Provided by (Used in) Financing Activities 2K USD -93.9%
Net Cash Provided by (Used in) Investing Activities 30K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 1.82M shares +0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.4M USD +61.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.6M USD -39.8%
Deferred Tax Assets, Valuation Allowance 161M USD +14.5%
Deferred Tax Assets, Gross 164M USD +11.2%
Operating Lease, Liability 18.8M USD -7.78%
Depreciation 3.3M USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 23.4M USD -10.8%
Property, Plant and Equipment, Gross 16M USD +5.44%
Operating Lease, Liability, Current 2.92M USD +6.84%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.14M USD +5.86%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.06M USD +126%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -14.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.64M USD -21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.24M USD +5.89%
Deferred Tax Assets, Operating Loss Carryforwards 81.7M USD +22.5%
Unrecognized Tax Benefits 10.3M USD +15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.33M USD +5.88%
Operating Lease, Payments 343K USD +18.7%
Deferred Tax Assets, Net of Valuation Allowance 3.67M USD -50.9%
Share-based Payment Arrangement, Expense 3.48M USD -28%